世界の子宮疾患治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Uterine Diseases Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5004 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、子宮疾患治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（薬物治療、外科治療）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・子宮疾患治療薬の市場動向 ・企業の競争状況、市場シェア ・子宮疾患治療薬の種類別市場規模と予測2016-2027（薬物治療、外科治療） ・子宮疾患治療薬の用途別市場規模と予測2016-2027（病院、クリニック、その他） ・子宮疾患治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・子宮疾患治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・子宮疾患治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・子宮疾患治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・子宮疾患治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Abbot、Merck、GlaxoSmithKline、Pfizer、AstraZeneca、Roche、Novartis、AbbVie、Neurocrime Biosciences、Bristol-Myers Squibb、Myovant Sciences、Eli Lily） ・結論

Uterus is the muscle organ in female reproductive system, which plays a great role in female reproduction and fetal development. The incidence of uterine diseases is also very high, so the treatment of uterine diseases is particularly important.

Market Analysis and Insights: Global Uterine Diseases Therapeutics Market
The global Uterine Diseases Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Uterine Diseases Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Uterine Diseases Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Uterine Diseases Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Uterine Diseases Therapeutics market.

Global Uterine Diseases Therapeutics Scope and Market Size
Uterine Diseases Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Uterine Diseases Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Medicinal Treatments
Surgical Treatments

Segment by Application
Hospital
Clinic
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Abbot
Merck
GlaxoSmithKline
Pfizer
AstraZeneca
Roche
Novartis
AbbVie
Neurocrime Biosciences
Bristol-Myers Squibb
Myovant Sciences
Eli Lily

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Uterine Diseases Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Medicinal Treatments
1.2.3 Surgical Treatments
1.3 Market by Application
1.3.1 Global Uterine Diseases Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Uterine Diseases Therapeutics Market Perspective (2016-2027)
2.2 Uterine Diseases Therapeutics Growth Trends by Regions
2.2.1 Uterine Diseases Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Uterine Diseases Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Uterine Diseases Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Uterine Diseases Therapeutics Industry Dynamic
2.3.1 Uterine Diseases Therapeutics Market Trends
2.3.2 Uterine Diseases Therapeutics Market Drivers
2.3.3 Uterine Diseases Therapeutics Market Challenges
2.3.4 Uterine Diseases Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Uterine Diseases Therapeutics Players by Revenue
3.1.1 Global Top Uterine Diseases Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Uterine Diseases Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Uterine Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Uterine Diseases Therapeutics Revenue
3.4 Global Uterine Diseases Therapeutics Market Concentration Ratio
3.4.1 Global Uterine Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Uterine Diseases Therapeutics Revenue in 2020
3.5 Uterine Diseases Therapeutics Key Players Head office and Area Served
3.6 Key Players Uterine Diseases Therapeutics Product Solution and Service
3.7 Date of Enter into Uterine Diseases Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Uterine Diseases Therapeutics Breakdown Data by Type
4.1 Global Uterine Diseases Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Uterine Diseases Therapeutics Forecasted Market Size by Type (2022-2027)

5 Uterine Diseases Therapeutics Breakdown Data by Application
5.1 Global Uterine Diseases Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Uterine Diseases Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Uterine Diseases Therapeutics Market Size (2016-2027)
6.2 North America Uterine Diseases Therapeutics Market Size by Type
6.2.1 North America Uterine Diseases Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Uterine Diseases Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Uterine Diseases Therapeutics Market Size by Type (2016-2027)
6.3 North America Uterine Diseases Therapeutics Market Size by Application
6.3.1 North America Uterine Diseases Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Uterine Diseases Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Uterine Diseases Therapeutics Market Size by Application (2016-2027)
6.4 North America Uterine Diseases Therapeutics Market Size by Country
6.4.1 North America Uterine Diseases Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Uterine Diseases Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Uterine Diseases Therapeutics Market Size (2016-2027)
7.2 Europe Uterine Diseases Therapeutics Market Size by Type
7.2.1 Europe Uterine Diseases Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Uterine Diseases Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Uterine Diseases Therapeutics Market Size by Type (2016-2027)
7.3 Europe Uterine Diseases Therapeutics Market Size by Application
7.3.1 Europe Uterine Diseases Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Uterine Diseases Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Uterine Diseases Therapeutics Market Size by Application (2016-2027)
7.4 Europe Uterine Diseases Therapeutics Market Size by Country
7.4.1 Europe Uterine Diseases Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Uterine Diseases Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Uterine Diseases Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Uterine Diseases Therapeutics Market Size by Type
8.2.1 Asia-Pacific Uterine Diseases Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Uterine Diseases Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Uterine Diseases Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Uterine Diseases Therapeutics Market Size by Application
8.3.1 Asia-Pacific Uterine Diseases Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Uterine Diseases Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Uterine Diseases Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Uterine Diseases Therapeutics Market Size by Region
8.4.1 Asia-Pacific Uterine Diseases Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Uterine Diseases Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Uterine Diseases Therapeutics Market Size (2016-2027)
9.2 Latin America Uterine Diseases Therapeutics Market Size by Type
9.2.1 Latin America Uterine Diseases Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Uterine Diseases Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Uterine Diseases Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Uterine Diseases Therapeutics Market Size by Application
9.3.1 Latin America Uterine Diseases Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Uterine Diseases Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Uterine Diseases Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Uterine Diseases Therapeutics Market Size by Country
9.4.1 Latin America Uterine Diseases Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Uterine Diseases Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Uterine Diseases Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Uterine Diseases Therapeutics Market Size by Type
10.2.1 Middle East & Africa Uterine Diseases Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Uterine Diseases Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Uterine Diseases Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Uterine Diseases Therapeutics Market Size by Application
10.3.1 Middle East & Africa Uterine Diseases Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Uterine Diseases Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Uterine Diseases Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Uterine Diseases Therapeutics Market Size by Country
10.4.1 Middle East & Africa Uterine Diseases Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Uterine Diseases Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Abbot
11.1.1 Abbot Company Details
11.1.2 Abbot Business Overview
11.1.3 Abbot Uterine Diseases Therapeutics Introduction
11.1.4 Abbot Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.1.5 Abbot Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Uterine Diseases Therapeutics Introduction
11.2.4 Merck Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.2.5 Merck Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Uterine Diseases Therapeutics Introduction
11.3.4 GlaxoSmithKline Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.3.5 GlaxoSmithKline Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Uterine Diseases Therapeutics Introduction
11.4.4 Pfizer Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Uterine Diseases Therapeutics Introduction
11.5.4 AstraZeneca Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.5.5 AstraZeneca Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Uterine Diseases Therapeutics Introduction
11.6.4 Roche Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.6.5 Roche Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Uterine Diseases Therapeutics Introduction
11.7.4 Novartis Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.7.5 Novartis Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Uterine Diseases Therapeutics Introduction
11.8.4 AbbVie Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.8.5 AbbVie Recent Development
11.9 Neurocrime Biosciences
11.9.1 Neurocrime Biosciences Company Details
11.9.2 Neurocrime Biosciences Business Overview
11.9.3 Neurocrime Biosciences Uterine Diseases Therapeutics Introduction
11.9.4 Neurocrime Biosciences Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.9.5 Neurocrime Biosciences Recent Development
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Details
11.10.2 Bristol-Myers Squibb Business Overview
11.10.3 Bristol-Myers Squibb Uterine Diseases Therapeutics Introduction
11.10.4 Bristol-Myers Squibb Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.10.5 Bristol-Myers Squibb Recent Development
11.11 Myovant Sciences
11.11.1 Myovant Sciences Company Details
11.11.2 Myovant Sciences Business Overview
11.11.3 Myovant Sciences Uterine Diseases Therapeutics Introduction
11.11.4 Myovant Sciences Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.11.5 Myovant Sciences Recent Development
11.12 Eli Lily
11.12.1 Eli Lily Company Details
11.12.2 Eli Lily Business Overview
11.12.3 Eli Lily Uterine Diseases Therapeutics Introduction
11.12.4 Eli Lily Revenue in Uterine Diseases Therapeutics Business (2016-2021)
11.12.5 Eli Lily Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Uterine Diseases Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Medicinal Treatments
Table 3. Key Players of Surgical Treatments
Table 4. Global Uterine Diseases Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Uterine Diseases Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Uterine Diseases Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Uterine Diseases Therapeutics Market Share by Regions (2016-2021)
Table 8. Global Uterine Diseases Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Uterine Diseases Therapeutics Market Share by Regions (2022-2027)
Table 10. Uterine Diseases Therapeutics Market Trends
Table 11. Uterine Diseases Therapeutics Market Drivers
Table 12. Uterine Diseases Therapeutics Market Challenges
Table 13. Uterine Diseases Therapeutics Market Restraints
Table 14. Global Uterine Diseases Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Uterine Diseases Therapeutics Market Share by Players (2016-2021)
Table 16. Global Top Uterine Diseases Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Uterine Diseases Therapeutics as of 2020)
Table 17. Ranking of Global Top Uterine Diseases Therapeutics Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Uterine Diseases Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Uterine Diseases Therapeutics Product Solution and Service
Table 21. Date of Enter into Uterine Diseases Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Uterine Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Uterine Diseases Therapeutics Revenue Market Share by Type (2016-2021)
Table 25. Global Uterine Diseases Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Uterine Diseases Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Uterine Diseases Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Uterine Diseases Therapeutics Revenue Market Share by Application (2016-2021)
Table 29. Global Uterine Diseases Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Uterine Diseases Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Uterine Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Uterine Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Uterine Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Uterine Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Uterine Diseases Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Uterine Diseases Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Uterine Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Uterine Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Uterine Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Uterine Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Uterine Diseases Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Uterine Diseases Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Uterine Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Uterine Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Uterine Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Uterine Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Uterine Diseases Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Uterine Diseases Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Uterine Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Uterine Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Uterine Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Uterine Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Uterine Diseases Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Uterine Diseases Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Uterine Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Uterine Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Uterine Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Uterine Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Uterine Diseases Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Uterine Diseases Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 61. Abbot Company Details
Table 62. Abbot Business Overview
Table 63. Abbot Uterine Diseases Therapeutics Product
Table 64. Abbot Revenue in Uterine Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 65. Abbot Recent Development
Table 66. Merck Company Details
Table 67. Merck Business Overview
Table 68. Merck Uterine Diseases Therapeutics Product
Table 69. Merck Revenue in Uterine Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 70. Merck Recent Development
Table 71. GlaxoSmithKline Company Details
Table 72. GlaxoSmithKline Business Overview
Table 73. GlaxoSmithKline Uterine Diseases Therapeutics Product
Table 74. GlaxoSmithKline Revenue in Uterine Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 75. GlaxoSmithKline Recent Development
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Uterine Diseases Therapeutics Product
Table 79. Pfizer Revenue in Uterine Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. AstraZeneca Company Details
Table 82. AstraZeneca Business Overview
Table 83. AstraZeneca Uterine Diseases Therapeutics Product
Table 84. AstraZeneca Revenue in Uterine Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 85. AstraZeneca Recent Development
Table 86. Roche Company Details
Table 87. Roche Business Overview
Table 88. Roche Uterine Diseases Therapeutics Product
Table 89. Roche Revenue in Uterine Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 90. Roche Recent Development
Table 91. Novartis Company Details
Table 92. Novartis Business Overview
Table 93. Novartis Uterine Diseases Therapeutics Product
Table 94. Novartis Revenue in Uterine Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 95. Novartis Recent Development
Table 96. AbbVie Company Details
Table 97. AbbVie Business Overview
Table 98. AbbVie Revenue in Uterine Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 99. AbbVie Recent Development
Table 100. Neurocrime Biosciences Company Details
Table 101. Neurocrime Biosciences Business Overview
Table 102. Neurocrime Biosciences Uterine Diseases Therapeutics Product
Table 103. Neurocrime Biosciences Revenue in Uterine Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 104. Neurocrime Biosciences Recent Development
Table 105. Bristol-Myers Squibb Company Details
Table 106. Bristol-Myers Squibb Business Overview
Table 107. Bristol-Myers Squibb Uterine Diseases Therapeutics Product
Table 108. Bristol-Myers Squibb Revenue in Uterine Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 109. Bristol-Myers Squibb Recent Development
Table 110. Myovant Sciences Company Details
Table 111. Myovant Sciences Business Overview
Table 112. Myovant Sciences Uterine Diseases Therapeutics Product
Table 113. Myovant Sciences Revenue in Uterine Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 114. Myovant Sciences Recent Development
Table 115. Eli Lily Company Details
Table 116. Eli Lily Business Overview
Table 117. Eli Lily Uterine Diseases Therapeutics Product
Table 118. Eli Lily Revenue in Uterine Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 119. Eli Lily Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Uterine Diseases Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Medicinal Treatments Features
Figure 3. Surgical Treatments Features
Figure 4. Global Uterine Diseases Therapeutics Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Other Case Studies
Figure 8. Uterine Diseases Therapeutics Report Years Considered
Figure 9. Global Uterine Diseases Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Uterine Diseases Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Uterine Diseases Therapeutics Market Share by Regions: 2020 VS 2027
Figure 12. Global Uterine Diseases Therapeutics Market Share by Regions (2022-2027)
Figure 13. Global Uterine Diseases Therapeutics Market Share by Players in 2020
Figure 14. Global Top Uterine Diseases Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Uterine Diseases Therapeutics as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Uterine Diseases Therapeutics Revenue in 2020
Figure 16. Global Uterine Diseases Therapeutics Revenue Market Share by Type (2016-2021)
Figure 17. Global Uterine Diseases Therapeutics Revenue Market Share by Type (2022-2027)
Figure 18. North America Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Uterine Diseases Therapeutics Market Share by Type (2016-2027)
Figure 20. North America Uterine Diseases Therapeutics Market Share by Application (2016-2027)
Figure 21. North America Uterine Diseases Therapeutics Market Share by Country (2016-2027)
Figure 22. United States Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Uterine Diseases Therapeutics Market Share by Type (2016-2027)
Figure 26. Europe Uterine Diseases Therapeutics Market Share by Application (2016-2027)
Figure 27. Europe Uterine Diseases Therapeutics Market Share by Country (2016-2027)
Figure 28. Germany Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Uterine Diseases Therapeutics Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Uterine Diseases Therapeutics Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Uterine Diseases Therapeutics Market Share by Region (2016-2027)
Figure 38. China Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Uterine Diseases Therapeutics Market Share by Type (2016-2027)
Figure 46. Latin America Uterine Diseases Therapeutics Market Share by Application (2016-2027)
Figure 47. Latin America Uterine Diseases Therapeutics Market Share by Country (2016-2027)
Figure 48. Mexico Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Uterine Diseases Therapeutics Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Uterine Diseases Therapeutics Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Uterine Diseases Therapeutics Market Share by Country (2016-2027)
Figure 54. Turkey Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Uterine Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Abbot Revenue Growth Rate in Uterine Diseases Therapeutics Business (2016-2021)
Figure 58. Merck Revenue Growth Rate in Uterine Diseases Therapeutics Business (2016-2021)
Figure 59. GlaxoSmithKline Revenue Growth Rate in Uterine Diseases Therapeutics Business (2016-2021)
Figure 60. Pfizer Revenue Growth Rate in Uterine Diseases Therapeutics Business (2016-2021)
Figure 61. AstraZeneca Revenue Growth Rate in Uterine Diseases Therapeutics Business (2016-2021)
Figure 62. Roche Revenue Growth Rate in Uterine Diseases Therapeutics Business (2016-2021)
Figure 63. Novartis Revenue Growth Rate in Uterine Diseases Therapeutics Business (2016-2021)
Figure 64. AbbVie Revenue Growth Rate in Uterine Diseases Therapeutics Business (2016-2021)
Figure 65. Neurocrime Biosciences Revenue Growth Rate in Uterine Diseases Therapeutics Business (2016-2021)
Figure 66. Bristol-Myers Squibb Revenue Growth Rate in Uterine Diseases Therapeutics Business (2016-2021)
Figure 67. Myovant Sciences Revenue Growth Rate in Uterine Diseases Therapeutics Business (2016-2021)
Figure 68. Eli Lily Revenue Growth Rate in Uterine Diseases Therapeutics Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

---